Improvement in a patient with hypereosinophilic syndrome after initiation of dupilumab treatment
Sign Up to like & getrecommendations! Published in 2020 at "JAAD Case Reports"
DOI: 10.1016/j.jdcr.2020.02.030
Abstract: IL: interleukin INTRODUCTION Hypereosinophilic syndromes are rare disorders defined by persistent peripheral eosinophilia (absolute eosinophil count[1.53 10/L) plus evidence of organ involvement. They are subclassified into primary or myeloid hypereosinophilic syndromes, secondary or lymphocytic hypereosinophilic… read more here.
Keywords: hypereosinophilic syndrome; treatment; dupilumab treatment; secondary lymphocytic ... See more keywords
Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of dermatological science"
DOI: 10.1016/j.jdermsci.2018.01.016
Abstract: BACKGROUND Dupilumab, a fully human monoclonal antibody against the interleukin-4-receptor α subunit, has been developed and used in clinical trials to treat atopic dermatitis (AD). OBJECTIVE We aimed to assess the overall efficacy and safety… read more here.
Keywords: atopic dermatitis; dupilumab; dupilumab treatment; analysis ... See more keywords
Non-Infectious Uveitis Secondary to Dupilumab Treatment in Atopic Dermatitis Patients Shows a Pro-Inflammatory Molecular Profile.
Sign Up to like & getrecommendations! Published in 2023 at "Ocular immunology and inflammation"
DOI: 10.1080/09273948.2023.2182325
Abstract: Severe uveitis is a rare complication of interleukin-4 receptor alpha blocking by dupilumab in topic dermatitis (AD) patients. The aim of this study was to describe five moderate-to-severe AD patients who developed uveitis during dupilumab… read more here.
Keywords: uveitis; non infectious; dupilumab treatment; infectious uveitis ... See more keywords
Dupilumab for the treatment of asthma
Sign Up to like & getrecommendations! Published in 2017 at "Expert Opinion on Investigational Drugs"
DOI: 10.1080/13543784.2017.1282458
Abstract: ABSTRACT Introduction: Dupilumab (REGN668/SAR231893), produced by a collaboration between Regeneron and Sanofi, is a monoclonal antibody currently in phase III for moderate-to-severe asthma. Dupilumab is directed against the α-subunit of the interleukin (IL)-4 receptor and… read more here.
Keywords: asthma dupilumab; dupilumab treatment; severe asthma; dupilumab ... See more keywords
Impact of the COVID-19 pandemic and lockdown on the clinical response to dupilumab treatment and the psychological status of non-infected atopic patients
Sign Up to like & getrecommendations! Published in 2021 at "European Journal of Dermatology"
DOI: 10.1684/ejd.2021.4135
Abstract: Dupilumab is an effective treatment for atopic dermatitis and was found to improve results of clinician- and patient-oriented tests with relevant benefits across multiple domains related to the disease. To investigate the effects of significant… read more here.
Keywords: dupilumab treatment; oriented tests; patient oriented; pandemic lockdown ... See more keywords
Dupilumab in the treatment of asthma.
Sign Up to like & getrecommendations! Published in 2019 at "Immunotherapy"
DOI: 10.2217/imt-2019-0008
Abstract: Dupilumab is a fully human monoclonal IgG4 antibody that blocks IL-4 and IL-13 signaling. Its efficacy has been assessed across a range of atopic diseases, due to its ability to inhibit T helper cell 2… read more here.
Keywords: dupilumab; dupilumab treatment; treatment; treatment asthma ... See more keywords